lscfa wrote:
Rahul Sarugaser
Congrats on the rep growth this year. So I just wanted to check in on the guidance of $180 million top line by the end of calendar year, given that we've seen how much in July, partial contribution. How is the company tracking towards that guidance?
Gregory Crawford
Yes, sure. So that was some guidance that was given on exiting in that our fiscal Q1 '23 number here in that, which is the calendar in that. So I'll say we do have a little, ways to go. We haven't reported those numbers yet, and that will be in February. It's hard for us in that to predict the timing in that of some of these acquisitions in order to kind of give out in that exactly when that's going to happen, but we do have a very high confidence level in being able to meet that outlook.
Rahul Sarugaser
Okay. Great. And if you don't mind if I just drill a little bit further. So in order to meet that outlook, you probably need to be adding about $20 million in [indiscernible] just less than over Q1 towards the end of the calendar year. And so even if we estimate sort of smaller acquisitions, that's around 4-ish. So could you maybe give us a sense, even though timing is a little less unpredictable, how we should be thinking about the number of acquisitions in order to get that -- hit that target and sort of the general sort of size of those acquisitions to hit that target?
Gregory Crawford
Yes. Well, we continue to remain focused on all 3 prongs in that of our acquisition strategy in that. So with the smaller sized companies, say, 5 million are under and then also kind of those key -- turnkey respiratory in that, that would be in that $5 million to $20 million and then also in that continue proving through additional larger acquisitions. So it's really hard to kind of give what's going to make it to the finish line with that timing and that on those particular acquisitions, whether it's 1 or it's 3 and that to kind of get us there.